Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29516675)

  • 1. Do FHIT gene alterations play a role in human solid tumors?
    Silveira Zavalhia L; Weber Medeiros A; Oliveira Silva A; Vial Roehe A
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e214-e223. PubMed ID: 29516675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
    Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer.
    Holschneider CH; Baldwin RL; Tumber K; Aoyama C; Karlan BY
    Clin Cancer Res; 2005 Aug; 11(16):5756-63. PubMed ID: 16115913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms shaping the mutational landscape of the FRA3B/FHIT-deficient cancer genome.
    Saldivar JC; Park D
    Genes Chromosomes Cancer; 2019 May; 58(5):317-323. PubMed ID: 30242938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of the fragile histidine triad gene early in carcinogenesis: an update.
    Ishii H; Ozawa K; Furukawa Y
    J Exp Ther Oncol; 2003; 3(6):291-6. PubMed ID: 14678517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
    Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
    Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity in the fragile histidine triad (FHIT) locus and expression analysis of FHIT protein in patients with breast disorders.
    Rabelo RA; Antunes LM; Etchebehere RM; Nomelini RS; Nascentes GA; Murta EF; Pedrosa AL
    Clin Exp Obstet Gynecol; 2013; 40(1):89-94. PubMed ID: 23724516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
    Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.
    Zanesi N; Pekarsky Y; Croce CM
    Mutat Res; 2005 Dec; 591(1-2):103-9. PubMed ID: 16085127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of deletions at the FRA3B/FHIT locus in carcinogenesis.
    Huebner K; Druck T; Siprashvili Z; Croce CM; Kovatich A; McCue PA
    Recent Results Cancer Res; 1998; 154():200-15. PubMed ID: 10027001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of
    Simón-Carrasco L; Pietrini E; López-Contreras AJ
    Cell Cycle; 2024 Jan; 23(1):92-113. PubMed ID: 38234243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
    Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
    Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased fragile histidine triad gene protein expression is associated with worse prognosis in oral squamous carcinoma.
    Guerin LA; Hoffman HT; Zimmerman MB; Robinson RA
    Arch Pathol Lab Med; 2006 Feb; 130(2):158-64. PubMed ID: 16454554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
    Guidi E; Uboldi C; Ferretti L
    Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients.
    Petursdottir TE; Hafsteinsdottir SH; Jonasson JG; Moller PH; Thorsteinsdottir U; Huiping C; Egilsson V; Ingvarsson S
    Anticancer Res; 2002; 22(6A):3205-12. PubMed ID: 12530066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
    Ishii H; Vecchione A; Fong LY; Zanesi N; Trapasso F; Furukawa Y; Baffa R; Huebner K; Croce CM
    Curr Gene Ther; 2004 Mar; 4(1):53-63. PubMed ID: 15032614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.